Effects of silencing of mutant p53 gene in human lung adenocarcinoma cell line Anip973

Journal of Experimental and Clinical Cancer Research

Volumn 25, Issue 4, 2006, Pages 585-592

  Ma, L L ^a   Sun, W J ^a   Wang, Zh ^a   Zh, G Y ^a   Li, P ^a   Fu, Song Bin ^a,b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b Bio pharmaceutical Key Laboratory of Heilongjiang Province   (China)

Author keywords

'Gain of function' effects; Cell cycle; Mutant p53 gene; RNAi; TGF BMP pathway

Indexed keywords

BONE MORPHOGENETIC PROTEIN; COMPLEMENTARY DNA; GROWTH DIFFERENTIATION FACTOR 9; INHIBIN B; INVOLUCRIN; MUTANT PROTEIN; PROTEIN P27; PROTEIN P53; SOMATOMEDIN BINDING PROTEIN 3; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; DNA SCREENING; FLOW CYTOMETRY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION;

ADENOCARCINOMA; BASE SEQUENCE; CELL LINE, TUMOR; DNA PRIMERS; GENE SILENCING; GENES, P53; HUMANS; LUNG NEOPLASMS; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING;

EID: 33846539661     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Slee E.A., O'Connor D.J., Lu X.: To die or not to die: how does p53 decide? Oncogene. 23: 2809-2818, 2004.
2. Michael D., Oren M.: The p53 and Mdm2 families in cancer. Curr. Opin. Genet. Dev. 12: 53-59, 2002.
3. Carnero A., Hudson J.D., Hannon G.J., Beach D.H. Loss-of-function genetics in mammalian cells: the p53 tumor suppressor model. Nucleic Acids Res. 28: 2234-2241, 2000.
4. Olive K.P., Tuveson D.A., Ruhe Z.C., Yin B., Willis N.A., Bronson R.T., Crowley D., Jacks T.: Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119: 847-60, 2004.
5. Lang G.A., Iwakuma T., Suh Y.A., Liu G., Rao V.A., Parant J.M., Valentin-Vega Y.A., Terzian T., Caldwell L.C., Strong L.C., El-Naggar A.K., Lozano G.: Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119: 861-872, 2004.
6. Murphy K.L., Dennis A.P., Rosen J.M.: A gain of function p53 mutant promotes both genomic instability and cell survival in a novel p53-null mammary epithelial cell model. Faseb. J. 14: 2291-2302, 2000.
7. Matas D., Sigal A., Stambolsky P., Milyavsky M., Weisz L., Schwartz D., Goldfinger N., Rotter V.: Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis. Embo J. 20: 4163-4172, 2001.
8. Wistuba I.I., Gazdar A.F., Minna J.D.: Molecular genetics of small cell lung carcinoma. Semin. Oncol. 28: 3-13, 2001.
9. Gerwin B.I., Spillare E., Forrester K., Lehman T.A., Kispert J., Welsh J.A., et al.: Mutant p53 can induce tumorigenic conversion of human bronchial epithelial cells and reduce their responsiveness to a negative growth factor, transforming growth factor beta 1. Proc. Natl. Acad. Sci. U.S.A. 89(7): 2759-2763, 1992.
10. Gorgoulis V.G., Zacharatos P.V., Manolis E., Ikonomopoulos J.A., Damalas A., Lamprinopoulos C., et al.: Effects of p53 mutants derived from lung carcinomas on the p53-responsive element (p53KE) of the MDM2 gene. Br. J. Cancer 77(3): 374-384, 1998.
11. Blandino G., Levine A.J., and Oren M.: Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18(2): 477-485, 1999.
12. Scian M.J., Stagliano K.E., Ellis M.A., Hassan S., Bowman M., Miles M.F., Deb S.P., Deb S.: Modulation of gene expression by tumor-derived p53 mutants. Cancer Res. 64(20): 7447-7454, 2004.
13. Jackson E.L., Olive K.P., Tuveson D.A., Bronson R., Crowley D., Brown M., Jacks T.: The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res. 65(22): 10280-10288, 2005.
14. Marchetti A., Doglioni C., Barbareschi M., Buttitta F., Pellegrini S., Bertacca G., Chella A., Merlo G., Angeletti C.A., Dalla Palma P., Bevilacqua G.: p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. Oncogene 12: 1319-1324, 1996.
15. Selivanova G.: p53: fighting cancer. Curr. Cancer Drug. Targets 4: 385-402, 2004.
16. Sigal A., Rotter V.: Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res. 60: 6788-6793, 2000.
17. Zalcenstein A., Stambolsky P., Weisz L., Muller M., Wallach D., Goncharov T.M., Krammer P.H., Rotter V., Oren M.: Mutant p53 gain of function: repression of CD95 (Fas/APO-1) gene expression by tumor-associated p53 mutants. Oncogene 22: 5667-5676, 2003.
18. Hussain S.P., Hofseth L.J., Harris C.C.: Tumor suppressor genes: at the crossroads of molecular carcinogenesis, molecular epidemiology and human risk assessment. Lung Cancer 34 Suppl 2: 87-15, 2001.
19. Martinez L.A., Naguibneva I., Lehrmann H., Vervisch A., Tchenio T., Lozano G., Harel-Bellan A.: Synthetic small inhibiting RNAs: efficient tools to inactivate oncogenic mutations and restore p53 pathways. Proc. Natl. Acad. Sci. U.S.A. 99: 14849-14854, 2002.
20. Foster B.A., Coffey H.A., Morin M.J., Rastinejad F.: Pharmacological rescue of mutant p53 conformation and function. Science 286: 2507-2510, 1999.
21. Kuo M.Y., Hsu H.Y., Kok S.H., Kuo R.C., Yang H., Hahn L.J., Chiang C.P.: Prognostic role of p27(Kip1) expression in oral squamous cell carcinoma in Taiwan. Oral. Oncol. 38: 172-178, 2002.
22. Hayashi H., Ito T., Yazawa T., Ikeda M., Inayama Y., Nakatani Y., Kameda Y., Nakamura N., Kitamura H.: Reduced expression of p27/Kip1 is associated with the development of pulmonary adenocarcinoma. J. Pathol. 192: 26-31, 2000.
23. Cordenonsi M., Dupont S., Maretto S., Insinga A., Imbriano C., Piccolo S.: Links between tumor suppressors: p53 is required for TGF-beta gene responses by cooperating with Smads. Cell 113: 301-314, 2003.
24. Wakefield L.M., Roberts A.B.: TGF-beta signaling: positive and negative effects on tumorigenesis. Curr. Opin. Genet. Dev. 12: 22-29, 2002.
25. Dupont S., Zacchigna L., Adorno M., Soligo S., Volpin D., Piccolo S., Cordenonsi M.: Convergence of p53 and TGF-beta signaling networks. Cancer Lett. 213: 129-138, 2004.
26. Lebrun J.J., Vale W.W.: Activin and inhibin have antagonistic effects on ligand-dependent heteromerization of the type I and type II activin receptors and human erythroid differentiation. Mol. Cell. Biol. 17: 1682-1691, 1997.
27. Lewis K.A., Gray P.C., Blount A.L., MacConell L.A., Wiater E., Bilezikjian L.M., Vale W.: Betaglycan binds inhibin and can mediate functional antagonism of activin signalling. Nature 404: 411-414, 2000.
28. Wu X., Chen L., Brown C.A., Yan C., Matzuk M.M.: Interrelationship of growth differentiation factor 9 and inhibin in early folliculogenesis and ovarian tumorigenesis in mice. Mol. Endocrinol. 18: 1509-1519, 2004.
29. Buckbinder L., Talbott R., Velasco-Miguel S., Takenaka I., Faha B., Seizinger B.R., Kley N.: Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377: 646-649, 1995.
30. Werner H., Karnieli E., Rauscher F.J., LeRoith D.: Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor 1 receptor gene. Proc. Natl. Acad. Sci. USA 93: 8318-8323, 1996.